In pharmacokinetics, the term bioequivalence is used to assess the expected in-vivo biological equivalence of two different versions of a drug, where one of them is usually commercially available and is used as a reference drug.

If two products are said to be bioequivalent it’s expected that their behavior in the human body is, for all intents and purposes, the same.

The World Health Organization generally considers two formulations to be bioequivalent if a 90% confidence interval for the ratio of the generic/ tested product lies within an 80.00-125.00% acceptance range for the two observed parameters (AUC0-t and cmax).

For high-variable finished pharmaceutical products, the applicable acceptance range for the cmax parameter can be widened, or in cases of narrow therapeutic drugs, tightened.

Offering extensive experience in the field of bioequivalence studies from project design and documentation, through clinical and bioanalytical work complete with full statistical clinical reports, the QUINTA-ANALYTICA team comprises of multiple highly experienced principal investigators who are specialists in fields spanning internal medicine, cardiology, oncology, and pharmacology.

Ready to conduct your BE study? Get in touch with us today and discover your true pharma partner, QUINTA-ANALYTICA.

Additional News

  • 18 March 2024

    News from our newly opened clinic in Ostrava

    Our new Clinic in Ostrava (CZ) is gaining momentum step by step; therefore, we have some interesting news for you from the center of the action.

  • 19 December 2023

    Happy new year 2024

    As we bid farewell to 2023, it's time to express our deepest gratitude for the collaboration.

  • 4 December 2023

    Our new clinical unit in Ostrava comes to life

    It's a great pleasure to announce that after two years of hard work, the brand-new clinical unit in Ostrava with 36-beds capacity has been opened.